The Piazza Center - BPC-157 Banned by the FDA?: Discusses FDA's nuanced position and reasons for caution
Both oral and injectable versions are sold and studied strictly as research compounds
Disclosure of interest: Sheng Yang and Alastair Webb: nothing to disclose Poster Session II - NOVEL TARGET/ EXPERIMENTAL FIDINGS TO CLINICAL TRANSLATION 06.00 - NOVEL TARGET/ EXPERIMENTAL FIDINGS TO CLINICAL TRANSLATION - 06.02 - GENETICS, OMICS AND BIOMARKERS P1086 - ESOC25-803 ASSOCIATIONS OF MRI INDICES OF GLYMPHATIC FUNCTION AND DISEASE SEVERITY IN CADASIL Yunqing Ying 1 , Rong Zhou 1 , Xin Cheng 1 1 Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China Background and Aims: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common hereditary cerebral small vessel disease (CSVD)
I have more energy than when I was younger, and I am now 50 years old with multiple ailments that cause chronic fatigue
Indeed, studies on BPC-157 to date have more often featured injection rather than nasal delivery [21, 22]